Economics of antiretroviral treatment vs. circumcision for HIV prevention.
about
Review: [corrected] The changing face of the HIV epidemic in sub-Saharan AfricaAntiretroviral therapy for prevention of HIV transmission: implications for EuropeDynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature ReviewHIV treatment as prevention: contradictory perspectives from dynamic mathematical modelsAddressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation.Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda.The cost of demand creation activities and voluntary medical male circumcision targeting school-going adolescents in KwaZulu-Natal, South Africa.Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.Circumcision as a strategy to minimize HIV transmission.Attrition through multiple stages of pre-treatment and ART HIV care in South AfricaMeasuring the impact of non-monetary incentives on facility delivery in rural Zambia: a clustered randomised controlled trial.Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidenceHow much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United KingdomHow much does it cost to improve access to voluntary medical male circumcision among high-risk, low-income communities in Uganda?Estimated age and gender profile of individuals missed by a home-based HIV testing and counselling campaign in a Botswana community.In developed countries male circumcision prevalence is inversely related to HIV prevalence.Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered?Length of secondary schooling and risk of HIV infection in Botswana: evidence from a natural experiment.HIV Treatment and Prevention: A Simple Model to Determine Optimal InvestmentLong-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study.Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa.Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations.Safety Profile of PrePex Male Circumcision Device and Client Satisfaction With Adolescent Males Aged 13-17 Years in Zimbabwe.Assessing Progress, Impact, and Next Steps in Rolling Out Voluntary Medical Male Circumcision for HIV Prevention in 14 Priority Countries in Eastern and Southern Africa through 2014.Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda.Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment.Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.The HIV epidemic in Southern Africa - Is an AIDS-free generation possible?Who pays and why? Costs, effectiveness, and feasibility of HIV treatment as prevention.Foreskin and the molecular politics of risk.Male circumcision for protection against HIV infection in sub-Saharan Africa: the evidence in favour justifies the implementation now in progress.Circumcision is a primary preventive against HIV infection: Critique of a contrary meta-regression analysis by Van Howe.Male circumcision to prevent syphilis in 1855 and HIV in 1986 is supported by the accumulated scientific evidence to 2015: Response to Darby.Expertise or ideology? A response to Morris et al. 2016, 'Circumcision is a primary preventive against HIV infection: Critique of a contrary meta-regression analysis by Van Howe'.Veracity and rhetoric in paediatric medicine: a critique of Svoboda and Van Howe's response to the AAP policy on infant male circumcision.Modelling the human immunodeficiency virus (HIV) epidemic: A review of the substance and role of models in South Africa.Reconciling the science and policy divide: The reality of scaling up antiretroviral therapy in South Africa.Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a
P2860
Q27022927-EFC65E28-70F8-457B-9769-9480398D6AD9Q27023464-A5B8A616-C015-45A5-8039-3A1E7152D567Q28072167-CCDD3987-BACE-4F81-8F15-F65340F7E652Q28080917-D844579A-A24D-409D-BB89-1ECCD55AAB89Q30363571-25825D3F-4EE1-42D2-9DEA-2488D44AE0A1Q33634785-F65CF40E-4C66-4772-BA01-03F1E3A6CBEDQ33817502-9D3C3C8F-9DFA-4545-AAF0-7608D3AF4455Q33854542-A8C3A2FB-7480-41A0-888C-2BBB4A34820BQ33966505-82C75CC4-ACA9-4D66-9A43-272820A3F72BQ34351521-A93AA9E6-B674-47E2-9C8E-9B3D904C4031Q34374074-665BADC4-E3A7-49FB-A893-8F7D9B152E09Q34512531-F2EB8E2A-C779-4B1F-AEAC-2A04F68DC802Q34526461-62678E20-3CCF-4E86-B58B-1BBDBBD287A2Q35080217-D805E15C-CC00-46CC-A56B-263CFE8DF4A9Q35157015-14D66618-E167-4BF8-B939-52AF2FDE29D2Q35180958-D0014460-B168-48F6-ADB7-CCB09FD3391AQ35668867-B687FCA4-612A-4044-BC6F-020342108D6BQ35944781-2B38FC08-7A48-4DEB-BD0B-F6C43F8A1769Q36265694-F0800F8D-7323-4A75-9C63-987F1C190AE3Q36365683-F09AC55C-27B1-4AF4-B52F-E0A5EF35EB2BQ36642710-90EFBE33-9EF2-453E-B6E7-280FDE91AF9BQ36670480-4C4D302C-79B8-405B-A957-7E0D93B64DC3Q36835774-DCE6A6C8-C870-4588-809C-0CDB79737953Q37003069-03DA9509-0010-4937-B279-B0870B261360Q37074234-1427BD6E-5ED6-47C2-87AA-68560E20D910Q37114210-29FEB609-E9BA-4331-8CA1-6356CAB8DB74Q37265261-AB420882-C9D5-4CDE-878D-4E210AA5F5FDQ37386000-4B015269-6FE5-494B-91AC-06ECFB64A99EQ37505057-42CCF696-B21A-46F3-AD7D-4F9F1C8339B9Q38199989-43D66715-D091-4194-9F4E-1D702B929F7BQ38219957-5F238D0D-C3D7-4201-B9E0-F8FE0E0ABA9EQ38714370-ED05031D-C511-46FF-BF8A-F9C33DD8F96FQ39571729-5B5BBE5D-B89A-4DAD-AC3C-494FE5F2BC48Q39864872-379F6230-C232-42A6-8D98-95F932A3DC5AQ40325250-F19EB9FA-6A80-4144-950A-601B4A81AA4AQ40379346-8EDF39B9-0FF7-44E9-8447-F5965721109AQ44045974-1B3696A1-DAD0-420A-ADE0-CF76AD546B49Q53699090-9286FFC9-E29E-4FED-82BC-64242304400DQ53795602-834F0F5E-0316-496F-86BC-A655A21D721DQ55546871-DB62E5EA-0F8E-41FD-AA00-2CD0DFC856E3
P2860
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@ast
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@en
type
label
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@ast
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@en
prefLabel
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@ast
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@en
P2860
P356
P1476
Economics of antiretroviral treatment vs. circumcision for HIV prevention.
@en
P2093
David E Bloom
P2860
P304
21271-21276
P356
10.1073/PNAS.1209017110
P407
P577
2012-12-06T00:00:00Z